Neoadjuvant therapy-induced sarcopenia, reduced OS linked in pancreatic ductal adenocarcinoma

Neoadjuvant therapy-induced sarcopenia in patients who underwent neoadjuvant therapy for pancreatic ductal adenocarcinoma correlated with increased disease recurrence and overall mortality, and reduced overall survival, according to a presentation from Digestive Disease Week.“Patients who have pancreatic cancer are being preferentially treated with chemotherapy and/or radiation before surgery to ensure complete delivery while they are healthy,” Motaz Qadan, MD, PhD, from Massachusetts General Hospital in Boston, told Healio Gastroenterology and Liver Disease. “However, weRead More

Share on facebook
Share on twitter
Share on linkedin